Haberkorn U, Henze M, Altmann A, Jiang S, Morr I, Mahmut M, Peschke P, Kübler W, Debus J, Eisenhut M
Department of Nuclear Medicine, University of Heidelberg, Germany.
J Nucl Med. 2001 Feb;42(2):317-25.
The characteristic feature of thyroid cells of taking up iodide enables benign thyroid diseases and differentiated thyroid carcinoma to be successfully treated with radioiodide therapy. The transport of iodide across the cell membrane is mediated by the human NaI symporter (hNIS). We therefore investigated whether the accumulation of iodide may be induced by the retroviral transfer of the hNIS gene in nonthyroid tumor cells.
With use of a bicistronic retroviral vector for the transfer of the hNIS coding sequence and the hygromycin resistance gene, rat Morris hepatoma (MH3924A) cells were infected with retroviral particles and 32 hNIS-expressing cell lines were generated by hygromycin selection. After incubation of the genetically modified and wild-type hepatoma cells and the rat thyroid cell line FRTL5 with Na125I, the uptake and efflux of iodide were determined. In addition, the iodide distribution in rats bearing wild-type and genetically modified hepatomas was monitored.
Genetically modified MH3924A cell lines accumulated up to 235 times more iodide than did noninfected hepatoma cells. The maximal iodide uptake in the cells was observed after 60 min incubation time. Competition experiments in the presence of sodium perchlorate revealed a dose-dependent decrease of iodide uptake (87%-92%). Moreover, carbonyl cyanide p-trifluoromethoxyphenylhydrazone led to a loss of accumulated I- (32%), whereas 4,4'-diisothiocyano-2,2'-disulfonic acid stilbene increased the I- uptake into the cells (22%). However, a rapid efflux of the radioactivity (80%) was observed during the first 10 min after 125I(-)-containing medium had been replaced by nonradioactive medium. In rats, the hNIS-expressing tumors accumulated six times more iodide than did the contralateral wild-type tumor as monitored by scintigraphy. The ex vivo quantitation of the iodide content performed 1 h after tracer administration in 1 g of tumor tissue revealed a 17-fold higher iodide accumulation in the genetically modified tumors. In accordance with the in vitro data, we also observed a rapid efflux of radioactivity from the tumor in vivo.
The transduction of the hNIS gene per se is sufficient to induce 125I transport in Morris hepatoma cells in vitro and in vivo. With regard to a therapeutic application, however, additional conditions need to be defined that inhibit the iodide efflux from the tumor cells.
甲状腺细胞摄取碘化物的特性使得良性甲状腺疾病和分化型甲状腺癌能够通过放射性碘疗法成功治疗。碘化物跨细胞膜的转运由人类钠碘同向转运体(hNIS)介导。因此,我们研究了hNIS基因的逆转录病毒转移是否可诱导非甲状腺肿瘤细胞摄取碘化物。
使用双顺反子逆转录病毒载体转移hNIS编码序列和潮霉素抗性基因,用逆转录病毒颗粒感染大鼠莫里斯肝癌(MH3924A)细胞,并通过潮霉素筛选产生32个表达hNIS的细胞系。将基因改造的和野生型肝癌细胞以及大鼠甲状腺细胞系FRTL5与Na125I孵育后,测定碘化物的摄取和流出。此外,监测携带野生型和基因改造肝癌的大鼠体内碘化物的分布。
基因改造的MH3924A细胞系摄取的碘化物比未感染的肝癌细胞多235倍。孵育60分钟后观察到细胞中碘化物的最大摄取量。在高氯酸钠存在下的竞争实验显示碘化物摄取呈剂量依赖性下降(87%-92%)。此外,羰基氰化物对三氟甲氧基苯腙导致积累的I-流失(32%),而4,4'-二异硫氰酸-2,2'-二磺酸芪增加了细胞对I-的摄取(22%)。然而,在用含125I(-)的培养基替换为无放射性培养基后的最初10分钟内,观察到放射性迅速流出(80%)。在大鼠中,通过闪烁显像监测,表达hNIS的肿瘤摄取的碘化物比同侧野生型肿瘤多6倍。在给予示踪剂1小时后,对1克肿瘤组织进行碘化物含量的离体定量分析,结果显示基因改造肿瘤中的碘化物积累高17倍。与体外数据一致,我们在体内也观察到肿瘤中放射性的快速流出。
hNIS基因的转导本身足以在体外和体内诱导莫里斯肝癌细胞转运125I。然而,就治疗应用而言,需要确定其他条件来抑制肿瘤细胞中碘化物的流出。